Description
Cladribine Injection, is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms.
Description
Mitoxantrone Hydrochloride interferes with the growth of certain cells of the body, especially cells that reproduce quickly, such as cancer cells, bone marrow cells, and skin cells.
Description
Azacitidine is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Description
Rituximab which is a monoclonal antibody (a protein) and anti-neoplastic(anti-cancer) agent. This medicine binds specifically to the CD20 antigen located on pre-B and mature B lymphocytes (a type of white blood cells). CD20 is present on more than 90% of B-cell non-Hodgkin’s lymphomas (NHL), a cancer that starts in the lymphocytes. By doing so, it causes the malignant cells to die.
Description
Trastuzumab contains the active substance Trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Trastuzumab binds to HER2 it stops the growth of such cells and causes them to die.
Description
Capecitabine is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoro pyrimidine therapy alone is preferred. Capecitabine monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen.
Description
Paclitaxel Injection is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection is indicated in combination with cisplatin.
Description
Bevacizumab contains the active substance called Bevacizumab with protein structure. It belongs to a class of medicines known as anti-neoplastic (anti-cancer) agents. Different types of anti-neoplastic agents exist but this medicine belongs to anti-angiogenic group. This group of medicines will block the process of blood vessels formation in the body which is known as angiogenesis. Bevacizumab which is a protein (monoclonal antibody) will bind to another protein called Vascular Endothelial Growth Factor (VEGF); that is found on the cells lining blood vessels.
Description
This medicine can be used in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). It can be used in combination with carboplatin and pembrolizumab for the initial treatment of patients with metastatic, non-squamous NSCLC. This indication is approved under accelerated approval based on tumor response rate and progression-free survival.
Description
Bortezomib is indicated for the treatment of patients with multiple myeloma, mantle cell lymphoma.
Description
IRINOTECAN HCL is indicated as a component of first-line therapy in combination with
5-fluorouracil(5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.
This medicine is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil based therapy.
Description
OXALIPLATIN Injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete.
Description
Busulfan is a drug that makes your body ready for bone marrow or stem cell transplantation.
This medication is presented as Concentrate, sterile solution and is available in 1 vial in a box, containing 60 mg per 10 ml solution. Each ml of the concentrated solution contains 6 mg of Busulfan. This medication is prescribed only for intravenous infusion.
Description
Fludarabine phosphate is an anticancer drug which prevent cancer spreading in your body. Fludarabine phosphate is used in treatment of Chronic Lymphocyte Leukemia (CLL) in B-cell lymphocytes.
Description
Abirateron acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Description
Eptacog alfa (Recombinant coagulation factor VIIa), belonging to a group of medicines called blood coagulation factors that are involved in blood clotting. Eptacog alfa is a vitamin K-dependent and works by activating the extrinsic pathway of the coagulation. It is structurally similar to human plasma derived factor VIIa.
Description
Sorafenib is indicated for the treatment of patients with unrespectable hepatocellular carcinoma (HCC).
Description
Lenalidomide is indicated for the treatment of patientswith transfusion dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)associated with a deletion 5q cytogenetic abnormality withor without additional cytogenetic abnormalities.
Description
Description
Calcium Folinate is indicated as an antidote to the toxic effects of folic acid antagonists such as methotrexate, pyrimethamine, or trimethoprim. Calcium Folinate also is indicated as a rescue after high-dose meyhotrexate therapy in osteosarcoma and as a part of chemotherapeutic treatment programs in the management of several forms of cancer.